Keytruda gets FDA review in cHL, NICE nod in NSCLC

Merck & Co. Inc. (NYSE:MRK) said FDA accepted and granted Priority Review to an sBLA for Keytruda pembrolizumab to treat refractory classical Hodgkin’s

Read the full 236 word article

User Sign In